{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:18:15Z","timestamp":1770297495520,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.050","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:45:38Z","timestamp":1493772338000},"page":"3153-3161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review"],"prefix":"10.1016","volume":"35","author":[{"given":"Carlos K.H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Y.W.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqiao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy L.K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.050_b0005","unstructured":"World Health Organization. Global Vaccine Action Plan 2011\u20132020; 2012."},{"key":"10.1016\/j.vaccine.2017.04.050_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2014.09.023","article-title":"Comparison of NITAG policies and working processes in selected developed countries","volume":"33","author":"Ricciardi","year":"2015","journal-title":"Vaccine"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2017.04.050_b0015","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.1016\/j.vaccine.2010.02.037","article-title":"The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2017.04.050_b0020","doi-asserted-by":"crossref","first-page":"A76","DOI":"10.1016\/j.vaccine.2010.02.038","article-title":"The Australian model of immunization advice and vaccine funding","volume":"28","author":"Nolan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0025","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0030","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(97)03253-4","article-title":"Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use","volume":"350","author":"Levine","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.050_b0035","doi-asserted-by":"crossref","first-page":"ii62","DOI":"10.1093\/heapol\/czr049","article-title":"National decision-making on adopting new vaccines: a systematic review","volume":"27","author":"Burchett","year":"2012","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.vaccine.2017.04.050_b0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","article-title":"Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community","volume":"34","author":"Ultsch","year":"2016","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2017.04.050_b0045","unstructured":"Department of Health. HKSAR Government, Scientific Committee on Vaccine Preventable Diseases, Centre for Health Protection."},{"key":"10.1016\/j.vaccine.2017.04.050_b0050","first-page":"22","article-title":"New childhood immunisation programme in Hong Kong","volume":"12","author":"Cheuk","year":"2007","journal-title":"Hong Kong Med Diary"},{"key":"10.1016\/j.vaccine.2017.04.050_b0055","unstructured":"Department of Health. Hong Kong reference framework for preventive care for childrenin primary care settings: module on immunisation. The Government of the Hong Kong Special Administrative Region; 2015."},{"key":"10.1016\/j.vaccine.2017.04.050_b0060","unstructured":"World Health Organization. WHO recommendations for routine immunization - summary tables; 2016."},{"key":"10.1016\/j.vaccine.2017.04.050_b0065","unstructured":"Hong Kong SAR Government. Overview of the Health Care System in Hong Kong; 2016."},{"key":"10.1016\/j.vaccine.2017.04.050_b0070","first-page":"461","article-title":"Vaccines against influenza WHO position paper \u2013 November 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.04.050_b0075","first-page":"416","article-title":"Is the Hospital Authority's drug formulary equitable and efficient?","volume":"14","author":"Lau","year":"2008","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.vaccine.2017.04.050_b0080","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40258-016-0266-x","article-title":"Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on decision making for cancer screening in Hong Kong: a systematic review","volume":"14","author":"Wong","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.vaccine.2017.04.050_b0085","unstructured":"World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE): threshold values for intervention cost-effectiveness by Region."},{"key":"10.1016\/j.vaccine.2017.04.050_b0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1741-7015-9-55","article-title":"Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal","volume":"9","author":"Hutubessy","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2017.04.050_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1741-7015-11-23","article-title":"Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts","volume":"11","author":"Jit","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2017.04.050_b0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200826030-00004","article-title":"Cost-effectiveness analyses of vaccination programmes","volume":"26","author":"Kim","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"Supplement 3","key":"10.1016\/j.vaccine.2017.04.050_b0105","doi-asserted-by":"crossref","first-page":"C80","DOI":"10.1016\/j.vaccine.2013.05.064","article-title":"Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines","volume":"31","author":"De la Hoz-Restrepo","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0110","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1016\/j.vaccine.2013.06.060","article-title":"Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review","volume":"31","author":"Fesenfeld","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.vaccine.2012.10.103","article-title":"Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review","volume":"31","author":"Ozawa","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.307.6905.670","article-title":"Economic evaluation and health care. What does it mean?","volume":"307","author":"Robinson","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.04.050_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-11-80","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"11","author":"Husereau","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2017.04.050_b0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40273-015-0266-y","article-title":"Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes","volume":"33","author":"Geng","year":"2015","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2017.04.050_b0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/oemed-2012-100668","article-title":"Worksite mental health interventions: a systematic review of economic evaluations","volume":"69","author":"Hamberg-van Reenen","year":"2012","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.vaccine.2017.04.050_b0140","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2017.04.050_b0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vaccine.2013.10.068","article-title":"Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents","volume":"32","author":"Choi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.050_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-8510(00)00140-8","article-title":"Cost-effectiveness study on influenza prevention in Hong Kong","volume":"56","author":"Fitzner","year":"2001","journal-title":"Health Policy"},{"key":"10.1016\/j.vaccine.2017.04.050_b0155","unstructured":"McGhee SM, Chau J, Wong LC, et al. Economic analysis on Haemophilus influenzae b, chickenpox, pneumococcal, hepatitis A and combination vaccines in the Childhood Immunisation Programme in Hong Kong. Final Report Project CHP-CE-02; 2008."},{"key":"10.1016\/j.vaccine.2017.04.050_b0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/00365548.2013.847529","article-title":"Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong","volume":"46","author":"Chui","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.050_b0165","doi-asserted-by":"crossref","unstructured":"Ho AM-H, Nelson EAS, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Childhood 2008; 93: 52\u201358.","DOI":"10.1136\/adc.2007.117879"},{"key":"10.1016\/j.vaccine.2017.04.050_b0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vhri.2013.01.012","article-title":"The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong","volume":"2","author":"Lee","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vaccine.2017.04.050_b0175","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jech.2008.081885","article-title":"Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities","volume":"63","author":"You","year":"2009","journal-title":"J Epidemiol Commun Health"},{"key":"10.1016\/j.vaccine.2017.04.050_b0180","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1524-4733.2009.00626.x","article-title":"Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2017.04.050_b0185","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12879-014-0618-9","article-title":"Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong","volume":"14","author":"You","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.050_b0190","unstructured":"Wu JT, Riley S, Lam TH. Modelling the potential impact of HPV vaccination on Hong Kong's cervical cancer burden. Final Report Project CHP-CE-05; 2012."},{"key":"10.1016\/j.vaccine.2017.04.050_b0195","unstructured":"World Health Organization. Vaccine Product, Price and Procurement (V3P) Web Platform; 2016."},{"key":"10.1016\/j.vaccine.2017.04.050_b0200","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes; 2008."},{"key":"10.1016\/j.vaccine.2017.04.050_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40273-013-0113-y","article-title":"Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies","volume":"32","author":"van de Vooren","year":"2014","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2017.04.050_b0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/21645515.2015.1067351","article-title":"Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong","volume":"12","author":"Wu","year":"2016","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.04.050_b0215","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","article-title":"Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines","volume":"32","author":"Newall","year":"2014","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2017.04.050_b0220","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/hec.3086","article-title":"The influence of cost-effectiveness and other factors on nice decisions","volume":"24","author":"Dakin","year":"2015","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2017.04.050_b0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730542X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1730542X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T05:52:49Z","timestamp":1535867569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1730542X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X1730542X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}